Matinas BioPharma Holdings, Inc.

MTNBAMEXHealthcare● Active

$0.83

+$0.04(+5.20%)

Market Cap$4609530

P/E Ratio—

52W High$3.09

52W Low$0.48

Avg Volume141K

Open$0.78

Beta1.68

Overview

Matinas BioPharma Holdings, Inc.（MTNB）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

mtnb · 股价预测 · 8 位分析师（近3月）· FMP · 更新于 2026年5月31日

分析师评级与共识

基于过去 3 个月内 8 位华尔街分析师

Buy

8 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 8 · 买入占比: 87.5%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $0.82

Matinas BioPharma Holdings, Inc.（MTNB）的分析师共识为 Buy，基于过去 3 个月内 8 位华尔街分析师的评级。MTNB 的 12 个月平均目标价为 $0.00，相对当前价 $0.82 代表 +0.0% 的潜在上行空间。

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-09	$0.86	↑ 5.00%	$0.85	$0.87

1-day model range: $0.85–$0.87. Peak: $0.87 (+5.00%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$1	$1	$1	-20.0%
2028	$1	$1	$1	-28.1%
2029	$1	$1	$1	-31.7%
2030	$0	$1	$1	-33.4%
2031	$0	—	$1	-34.2%

Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BULLISH

Based on 14 technical indicators

86%0%14%

12Buy

0Neutral

2Sell

RSI (14)77.2Overbought

MACDBULLISH

Refreshes daily from EOD close

Moving Averages · MTNB · Jun 8, 2026

Simple Moving Average (SMA)

MA 5$0.79BUY

MA 10$0.79BUY

MA 20$0.70BUY

MA 50$0.62BUY

MA 100$0.62BUY

MA 200$0.97SELL

Current $MTNB · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$0.80BUY

EMA 10$0.77BUY

EMA 20$0.73BUY

EMA 50$0.67BUY

EMA 100$0.69BUY

EMA 200$0.77BUY

Current $MTNB · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2024-10-31	Maxim Group	Downgrade ↓	Buy→Hold
2023-01-31	HC Wainwright & Co.	Maintains	Buy→Buy
2020-08-13	Aegis Capital	Maintains	Buy→Buy
2020-01-27	Piper Sandler	Maintains	Overweight→Overweight
2020-01-24	SunTrust Robinson Humphrey	Maintains	Buy→Buy
2019-06-26	H.C. Wainwright	Maintains	Buy→Buy
2019-05-17	BTIG Research	Maintains	Buy→Buy
2019-02-11	Roth Capital	Maintains	Buy→Buy
2018-11-13	Maxim Group	Maintains	Buy→Buy
2018-08-13	Maxim Group	Maintains	Buy→Buy

Maxim Group2024-10-31

Downgrade ↓

Buy→Hold

HC Wainwright & Co.2023-01-31

Maintains

Buy→Buy

Aegis Capital2020-08-13

Maintains

Buy→Buy

Piper Sandler2020-01-27

Maintains

Overweight→Overweight

SunTrust Robinson Humphrey2020-01-24

Maintains

Buy→Buy

H.C. Wainwright2019-06-26

Maintains

Buy→Buy

BTIG Research2019-05-17

Maintains

Buy→Buy

Roth Capital2019-02-11

Maintains

Buy→Buy

Maxim Group2018-11-13

Maintains

Buy→Buy

Maxim Group2018-08-13

Maintains

Buy→Buy

Wall Street analysts have recently issued updated ratings on Matinas BioPharma Holdings, Inc. (MTNB) stock. Of the recent 12 rating actions, 0 were upgrades and 1 were downgrades. 8 analysts currently cover MTNB.

分析师推荐趋势

Buy ratings1 → 0↓ 1

Hold ratings0 → 1↑ +1

Sell ratings0 → 0

MTNB analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$1M

↓ 99.5% YoY

Revenue Next Year

$64M

↑ 12683.4% YoY

EPS This Year

$-4.06

EPS Next Year

$-1.50

↓ 63.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast MTNB EPS of $-4.06 for the current fiscal year, based on estimates from 1 analysts. The MTNB revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

MTNB 股价预测由两类独立数据源支撑：来自 8 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。MTNB 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Buy。

MTNB 的短期预测（明日）为 $0.86（+5.00%）。 MTNB 对 2027 年的股价预测均值为 $1。 MTNB 对 2030 年的预测区间为 $0–$1。

Matinas BioPharma Holdings, Inc. 在 AMEX 上市，代码 MTNB。MTNB 在 2027 年的整体展望偏积极，在覆盖分析师中约 88% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

MTNB 预测 · 8 个问题

根据 8 位华尔街分析师，MTNB 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $0.82，隐含约 +0.0% 的上行空间。

MTNB 目标价MTNB 分析师目标价MTNB 12个月目标价目标价 MTNB

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.